Evidence map›Paper›PMID 35071110›Full record

ArticleAdvanced biomedical research2021

Eugenol Administration Improves Liver Damage Induced by a Fructose-Rich Diet.

Abbass Ali Niazi, Fatemeh Kourkinejad Gharaei, Zahra Saebinasab, Maryam Maleki, Fatemeh Maghool, Fatemeh Fereidooni, Tahereh Safari

Abstract read
In one paragraph

Article in Advanced biomedical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Abbass Ali NiaziDepartment of Pathology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
Fatemeh Kourkinejad GharaeiStudent Research Committee, Zahedan University of Medical Sciences, Zahedan, Iran.
Zahra SaebinasabStudent Research Committee, Zahedan University of Medical Sciences, Zahedan, Iran.
Maryam MalekiDepartment of Physiology, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran.
Fatemeh MaghoolPoursina Hakim Digestive Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Fatemeh FereidooniDepartment of Physiology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
Tahereh SafariDepartment of Physiology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundsThe prevalence of metabolic syndrome (MetS) is increasing in developing countries that affects the liver in a variety of ways. This study was designed to investigate the protective role of eugenol on liver damage caused by fructose-induced MetS. MATERIALS AND

methodsThirty male Wistar rats were randomly divided into five groups: 1: tap water (control), 2: fructose, 3: fructose + eugenol solvent, 4: fructose + eugenol 50 mg/kg, and 5: fructose + eugenol 100 mg/kg. At the end of the experiment, blood samples were taken for measurement fast blood glucose (FBG), serum glutamic-oxaloacetic transaminase (SGOT), serum glutamic pyruvate transaminase (SGPT), low-density lipoprotein, high-density lipoprotein, cholesterol, and triglyceride.

resultsFBG significantly increased in Group 2 compared to Group 1 (

conclusionEugenol may ameliorate liver damage in a rat model of fructose-induced MetS, and these protective effects may in part be mediated by improving antioxidant status and reducing oxidative stress and lipid peroxidation. It may also reduce hepatic inflammation and fat accumulation as well as fibrosis of liver cells.

Indexed as

Eugenolfatty liverfructosemetabolic syndrome

Identifiers

PMID35071110
PMCPMC8744418

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.